Despite advances in diagnosis and treatment, it is difficult to accurately predict the evolution of a given tumor therefore to evaluate the response of each patient to their treatment.

Hence, at similar condition and treatment levels, life expectation for two patients affected by apparently the same cancer spans from months to years.

The clinical and biological heterogeneity of cancers, reflecting their complex and combinatory molecular nature, are largely responsible for therapeutical failures.

Characterizing the genetic mechanisms initiating these diseases, scientists have defined new molecular classes of cancer, organized under the same diagnosis and the same treatment, thereby enlightening oncologists and their patients’ decision.

Pioneer in this booming field, Ipsogen markets more than 60 tests already used in routine in over 50 countries for the diagnosis, prognosis and follow-up of thousands of patients with leukemia. The Company is now also focusing on breast cancer; its initial goal will be to provide diagnostic information that remained unavailable until now.

Aiming for the world’s top spot in the molecular profiling of cancer, Ipsogen's diagnostic tools will make a difference for patients, the medical profession and society in general in all 5 continents.